作为耐火性消化不良症的补充疗法,皮纳维胺的有效性和安全性:一项随机对照试验
Thansita Kamolsripat1, Nithi Thinrungroj1, Kanokwan Pinyopornpanish1
1Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Chiang Mai University Chiang Mai Thailand.
概括
皮纳维化物,当添加到奥梅普拉时,在功能性消化不良 (FD) 症状缓解方面没有显著的益处. 治疗被发现是安全的,但与安慰剂相比,没有改善足够的缓解反应率或整体症状.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 功能性消化不良 (FD) 是一个重大的治疗挑战.
- 抗药物作为FD的辅助治疗的作用尚未得到充分证实.
研究的目的:
- 评估皮纳维化物作为对耐火性FD的奥梅普拉的补充疗法的疗效和安全性.
- 为了确定皮纳维胺是否能改善FD患者的症状缓解和生活质量.
主要方法:
- 进行了一项随机的,安慰剂对照试验,涉及耐火性消化不良的患者.
- 参与者在8周的时间里,除了服用奥梅普拉外,还要接受皮纳维酸 (50毫克,每天3次) 或安慰剂.
- 主要终点是充分缓解的响应率,次要结果包括症状得分和生活质量.
主要成果:
- 在任何时间点 (第2,4,6周和第8周) 中, pinaverium 化物和安慰剂组之间没有观察到足够的缓解反应率的统计学上显著差异.
- 两组之间症状得分和生活质量改善是可比的.
- 皮纳维和安慰剂组的不良事件发生率相似,表明安全性概况相似.
结论:
- 皮纳维化物是安全的治疗难治性消化不良,当作为补充剂使用奥梅普拉.
- 这项研究没有证明 pinaverium 化物在改善耐火性 FD 患者的症状或生活质量方面有显著的益处.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
313
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
313
Peptic Ulcer Disease IV: Management
91
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91
Gastroesophageal Reflux Disease II: Clinical Features and Management
80
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
80


